268 related articles for article (PubMed ID: 22293302)
1. New approaches to prophylactic human papillomavirus vaccines for cervical cancer prevention.
Gersch ED; Gissmann L; Garcea RL
Antivir Ther; 2012; 17(3):425-34. PubMed ID: 22293302
[TBL] [Abstract][Full Text] [Related]
2. Developments in L2-based human papillomavirus (HPV) vaccines.
Schellenbacher C; Roden RBS; Kirnbauer R
Virus Res; 2017 Mar; 231():166-175. PubMed ID: 27889616
[TBL] [Abstract][Full Text] [Related]
3. Developing vaccines against minor capsid antigen L2 to prevent papillomavirus infection.
Karanam B; Jagu S; Huh WK; Roden RB
Immunol Cell Biol; 2009; 87(4):287-99. PubMed ID: 19421199
[TBL] [Abstract][Full Text] [Related]
4. Prophylactic papillomavirus vaccines.
Ribeiro-Müller L; Müller M
Clin Dermatol; 2014; 32(2):235-47. PubMed ID: 24559559
[TBL] [Abstract][Full Text] [Related]
5. Salmonella enterica serovar Typhi Ty21a expressing human papillomavirus type 16 L1 as a potential live vaccine against cervical cancer and typhoid fever.
Fraillery D; Baud D; Pang SY; Schiller J; Bobst M; Zosso N; Ponci F; Nardelli-Haefliger D
Clin Vaccine Immunol; 2007 Oct; 14(10):1285-95. PubMed ID: 17687110
[TBL] [Abstract][Full Text] [Related]
6. Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.
Boxus M; Fochesato M; Miseur A; Mertens E; Dendouga N; Brendle S; Balogh KK; Christensen ND; Giannini SL
J Virol; 2016 Jul; 90(14):6314-25. PubMed ID: 27147749
[TBL] [Abstract][Full Text] [Related]
7. A novel HPV prophylactic peptide vaccine, designed by immunoinformatics and structural vaccinology approaches.
Negahdaripour M; Eslami M; Nezafat N; Hajighahramani N; Ghoshoon MB; Shoolian E; Dehshahri A; Erfani N; Morowvat MH; Ghasemi Y
Infect Genet Evol; 2017 Oct; 54():402-416. PubMed ID: 28780192
[TBL] [Abstract][Full Text] [Related]
8. Rational design of a triple-type human papillomavirus vaccine by compromising viral-type specificity.
Li Z; Song S; He M; Wang D; Shi J; Liu X; Li Y; Chi X; Wei S; Yang Y; Wang Z; Li J; Qian H; Yu H; Zheng Q; Yan X; Zhao Q; Zhang J; Gu Y; Li S; Xia N
Nat Commun; 2018 Dec; 9(1):5360. PubMed ID: 30560935
[TBL] [Abstract][Full Text] [Related]
9. In silico DNA vaccine designing against human papillomavirus (HPV) causing cervical cancer.
Gupta SK; Singh A; Srivastava M; Gupta SK; Akhoon BA
Vaccine; 2009 Dec; 28(1):120-31. PubMed ID: 19799841
[TBL] [Abstract][Full Text] [Related]
10. Generation and characterization of a preventive and therapeutic HPV DNA vaccine.
Kim D; Gambhira R; Karanam B; Monie A; Hung CF; Roden R; Wu TC
Vaccine; 2008 Jan; 26(3):351-60. PubMed ID: 18096279
[TBL] [Abstract][Full Text] [Related]
11. Production of human papillomavirus type 33 L1 major capsid protein and virus-like particles from Bacillus subtilis to develop a prophylactic vaccine against cervical cancer.
Baek JO; Seo JW; Kwon O; Park SM; Kim CH; Kim IH
Enzyme Microb Technol; 2012 Mar; 50(3):173-80. PubMed ID: 22305172
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity of a trivalent human papillomavirus L1 DNA-encapsidated, non-replicable baculovirus nanovaccine.
Cho H; Lee HJ; Heo YK; Cho Y; Gwon YD; Kim MG; Park KH; Oh YK; Kim YB
PLoS One; 2014; 9(4):e95961. PubMed ID: 24759938
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic HPV DNA vaccines.
Lin K; Roosinovich E; Ma B; Hung CF; Wu TC
Immunol Res; 2010 Jul; 47(1-3):86-112. PubMed ID: 20066511
[TBL] [Abstract][Full Text] [Related]
14. [Construction and identification of non-replication recombinant vaccinia virus co-expressing human papillomavirus type 16 L1/L2/E6/E7 proteins].
Huang W; Tian HW; Ren J; Fan JT; Zhao L; Bian T; Lu ZH; Ruan L
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2005 Sep; 19(3):240-3. PubMed ID: 16261206
[TBL] [Abstract][Full Text] [Related]
15. Characterization of an Escherichia coli-derived human papillomavirus type 16 and 18 bivalent vaccine.
Gu Y; Wei M; Wang D; Li Z; Xie M; Pan H; Wu T; Zhang J; Li S; Xia N
Vaccine; 2017 Aug; 35(35 Pt B):4637-4645. PubMed ID: 28736197
[TBL] [Abstract][Full Text] [Related]
16. Co-vaccination with adeno-associated virus vectors encoding human papillomavirus 16 L1 proteins and adenovirus encoding murine GM-CSF can elicit strong and prolonged neutralizing antibody.
Liu DW; Chang JL; Tsao YP; Huang CW; Kuo SW; Chen SL
Int J Cancer; 2005 Jan; 113(1):93-100. PubMed ID: 15386434
[TBL] [Abstract][Full Text] [Related]
17. Oral immunization with bacteriophage MS2-L2 VLPs protects against oral and genital infection with multiple HPV types associated with head & neck cancers and cervical cancer.
Zhai L; Yadav R; Kunda NK; Anderson D; Bruckner E; Miller EK; Basu R; Muttil P; Tumban E
Antiviral Res; 2019 Jun; 166():56-65. PubMed ID: 30926288
[TBL] [Abstract][Full Text] [Related]
18. Broad Neutralization Responses Against Oncogenic Human Papillomaviruses Induced by a Minor Capsid L2 Polytope Genetically Incorporated Into Bacterial Ferritin Nanoparticles.
Yang F; Mariz FC; Zhao X; Spagnoli G; Ottonello S; Müller M
Front Immunol; 2020; 11():606569. PubMed ID: 33343580
[TBL] [Abstract][Full Text] [Related]
19. Natural variants in the major neutralizing epitope of human papillomavirus minor capsid protein L2.
Seitz H; Schmitt M; Böhmer G; Kopp-Schneider A; Müller M
Int J Cancer; 2013 Feb; 132(3):E139-48. PubMed ID: 22961598
[TBL] [Abstract][Full Text] [Related]
20. [Advances in Understanding Carcinogenetic Mechanisms of the Human Papillomavirus and Vaccines Based on Virus-like Particles].
Zhao Z; Wang L; Ma B
Bing Du Xue Bao; 2015 Mar; 31(2):180-6. PubMed ID: 26164945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
